english.prescrire.org > Spotlight > Archives : 2022 > Cabotegravir (Vocabria°) and rilpivirine (Rekambys°) intramuscular injections in HIV infection

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2022 : 1 | 30 | 60

Cabotegravir (Vocabria°) and rilpivirine (Rekambys°) intramuscular injections in HIV infection

FEATURED REVIEW The standard treatment for patients with HIV infection is a combination of at least three antiretro­virals. An oral two-­drug regimen is sometimes considered. How do Prescrire's editors rate this combination, administered by intramuscular injection?
Full review (2 pages) available for download by subscribers.

Prescrire's rating

  •  POSSIBLY HELPFUL  When dual therapy rather than triple therapy is chosen for a patient with HIV infection, intramuscular injection of the cabotegravir + rilpivirine combination administered monthly, or once every two months, is an option for patients who would rather avoid daily oral dosing. In addition to the adverse effects of integrase inhibitors and non-nucleoside reverse transcriptase inhibitors, this two-drug regimen provokes frequent injection site reactions and can interact with other drugs, even after treatment discontinuation. Injectable antiretroviral therapy has a number of drawbacks. In particular, the injections are often painful, someone else must administer them, and adherence to the chosen dosing schedule is essential.


©Prescrire 1 April 2022

Source: "Cabotegravir (Vocabria°) and rilpivirine (Rekambys°) IM injections in HIV infection" Prescrire International 2022; 31 (236): 94-95. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Prescrire's rating:
 
Prescrire's rating  
  POSSIBLY HELPFUL
 

See also:

"Prescrire's ratings for new
drugs and new indications"
(February 2022)
Free


Read more:

All the subjects in
Prescrire's Spotlight
Free >